Evaluation of manganese -trans-1,2-diaminocyclohexane-N,N,N′, N′-tetraacetate complex (Cyclomang) as paramagnetic contrast agent for magnetic resonance imaging

V. Yu Usov, M. L. Belyanin, A. I. Bezlepkin, A. A. Churin, T. Yu Dubskaya, T. L. Vetoshkina, V. D. Filimonov

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Preclinical evaluation of a 0.5 M solution of the manganese(II) - trans-1,2-diaminocyclohexane-N,N,N′,N′-tetraacetate complex (Mn-DCTA, Cyclomang) has been carried out with a view to substitution of potentially toxic gadolinium-containing paramagnetic contrast agents for clinical MRI routines. The toxicological tests of Mn(II)-DCTA were performed on mice and rats. Liquid phantoms were used for evaluating the relaxivity of Mn(II)-DCTA in comparison to that of Gd(III)-DTPA and Mn-DTPA. The diagnostic imaging properties of Mn(II)-DCTA were quantitatively assessed on dogs with cerebral meningeomas (n = 10). The LD50 upon single administration in rats was above 17 ml/kg, thus slightly exceeding the corresponding values for of Gd(III)-DTPA and Mn-DTPA. The relaxivity of Mn(II)-DCTA amounted to R1 =3.68 (mM-1 · s-1) and did not differ significantly from the values known for Gd-DTPA and Mn-DTPA. Mn(II)-DCTA ensured high-intensity contrast of tumor areas in brain of dogs. It is concluded that Mn(II)-DCTA can be employed as a paramagnetic contrast agent in routine MRI studies and is worth further clinical evaluation.

Original languageEnglish
Pages (from-to)32-38
Number of pages7
JournalEksperimental'naya i Klinicheskaya Farmakologiya
Volume76
Issue number10
Publication statusPublished - 1 Jan 2013

Fingerprint

Magnetic resonance
Manganese
Contrast Media
Pentetic Acid
Magnetic Resonance Imaging
Imaging techniques
Gadolinium DTPA
Magnetic resonance imaging
Rats
Dogs
Poisons
Lethal Dose 50
Gadolinium
Diagnostic Imaging
1,2-cyclohexanediamine
CDTA
Toxicology
Tumors
Brain
Substitution reactions

Keywords

  • Manganeses(II) - trans-1,2-diaminocyclohexane-N,N,N′,N′- tetraacetate (Mn-DCTA)
  • MRI
  • Paramagnetic enhancement
  • Preclinical evaluation

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

Evaluation of manganese -trans-1,2-diaminocyclohexane-N,N,N′, N′-tetraacetate complex (Cyclomang) as paramagnetic contrast agent for magnetic resonance imaging. / Usov, V. Yu; Belyanin, M. L.; Bezlepkin, A. I.; Churin, A. A.; Dubskaya, T. Yu; Vetoshkina, T. L.; Filimonov, V. D.

In: Eksperimental'naya i Klinicheskaya Farmakologiya, Vol. 76, No. 10, 01.01.2013, p. 32-38.

Research output: Contribution to journalArticle

@article{003f2d90e90f4d0dbe5b270a9edc0564,
title = "Evaluation of manganese -trans-1,2-diaminocyclohexane-N,N,N′, N′-tetraacetate complex (Cyclomang) as paramagnetic contrast agent for magnetic resonance imaging",
abstract = "Preclinical evaluation of a 0.5 M solution of the manganese(II) - trans-1,2-diaminocyclohexane-N,N,N′,N′-tetraacetate complex (Mn-DCTA, Cyclomang) has been carried out with a view to substitution of potentially toxic gadolinium-containing paramagnetic contrast agents for clinical MRI routines. The toxicological tests of Mn(II)-DCTA were performed on mice and rats. Liquid phantoms were used for evaluating the relaxivity of Mn(II)-DCTA in comparison to that of Gd(III)-DTPA and Mn-DTPA. The diagnostic imaging properties of Mn(II)-DCTA were quantitatively assessed on dogs with cerebral meningeomas (n = 10). The LD50 upon single administration in rats was above 17 ml/kg, thus slightly exceeding the corresponding values for of Gd(III)-DTPA and Mn-DTPA. The relaxivity of Mn(II)-DCTA amounted to R1 =3.68 (mM-1 · s-1) and did not differ significantly from the values known for Gd-DTPA and Mn-DTPA. Mn(II)-DCTA ensured high-intensity contrast of tumor areas in brain of dogs. It is concluded that Mn(II)-DCTA can be employed as a paramagnetic contrast agent in routine MRI studies and is worth further clinical evaluation.",
keywords = "Manganeses(II) - trans-1,2-diaminocyclohexane-N,N,N′,N′- tetraacetate (Mn-DCTA), MRI, Paramagnetic enhancement, Preclinical evaluation",
author = "Usov, {V. Yu} and Belyanin, {M. L.} and Bezlepkin, {A. I.} and Churin, {A. A.} and Dubskaya, {T. Yu} and Vetoshkina, {T. L.} and Filimonov, {V. D.}",
year = "2013",
month = "1",
day = "1",
language = "English",
volume = "76",
pages = "32--38",
journal = "Eksperimental'naya i Klinicheskaya Farmakologiya",
issn = "0869-2092",
publisher = "Izdatelstvo Meditsina",
number = "10",

}

TY - JOUR

T1 - Evaluation of manganese -trans-1,2-diaminocyclohexane-N,N,N′, N′-tetraacetate complex (Cyclomang) as paramagnetic contrast agent for magnetic resonance imaging

AU - Usov, V. Yu

AU - Belyanin, M. L.

AU - Bezlepkin, A. I.

AU - Churin, A. A.

AU - Dubskaya, T. Yu

AU - Vetoshkina, T. L.

AU - Filimonov, V. D.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Preclinical evaluation of a 0.5 M solution of the manganese(II) - trans-1,2-diaminocyclohexane-N,N,N′,N′-tetraacetate complex (Mn-DCTA, Cyclomang) has been carried out with a view to substitution of potentially toxic gadolinium-containing paramagnetic contrast agents for clinical MRI routines. The toxicological tests of Mn(II)-DCTA were performed on mice and rats. Liquid phantoms were used for evaluating the relaxivity of Mn(II)-DCTA in comparison to that of Gd(III)-DTPA and Mn-DTPA. The diagnostic imaging properties of Mn(II)-DCTA were quantitatively assessed on dogs with cerebral meningeomas (n = 10). The LD50 upon single administration in rats was above 17 ml/kg, thus slightly exceeding the corresponding values for of Gd(III)-DTPA and Mn-DTPA. The relaxivity of Mn(II)-DCTA amounted to R1 =3.68 (mM-1 · s-1) and did not differ significantly from the values known for Gd-DTPA and Mn-DTPA. Mn(II)-DCTA ensured high-intensity contrast of tumor areas in brain of dogs. It is concluded that Mn(II)-DCTA can be employed as a paramagnetic contrast agent in routine MRI studies and is worth further clinical evaluation.

AB - Preclinical evaluation of a 0.5 M solution of the manganese(II) - trans-1,2-diaminocyclohexane-N,N,N′,N′-tetraacetate complex (Mn-DCTA, Cyclomang) has been carried out with a view to substitution of potentially toxic gadolinium-containing paramagnetic contrast agents for clinical MRI routines. The toxicological tests of Mn(II)-DCTA were performed on mice and rats. Liquid phantoms were used for evaluating the relaxivity of Mn(II)-DCTA in comparison to that of Gd(III)-DTPA and Mn-DTPA. The diagnostic imaging properties of Mn(II)-DCTA were quantitatively assessed on dogs with cerebral meningeomas (n = 10). The LD50 upon single administration in rats was above 17 ml/kg, thus slightly exceeding the corresponding values for of Gd(III)-DTPA and Mn-DTPA. The relaxivity of Mn(II)-DCTA amounted to R1 =3.68 (mM-1 · s-1) and did not differ significantly from the values known for Gd-DTPA and Mn-DTPA. Mn(II)-DCTA ensured high-intensity contrast of tumor areas in brain of dogs. It is concluded that Mn(II)-DCTA can be employed as a paramagnetic contrast agent in routine MRI studies and is worth further clinical evaluation.

KW - Manganeses(II) - trans-1,2-diaminocyclohexane-N,N,N′,N′- tetraacetate (Mn-DCTA)

KW - MRI

KW - Paramagnetic enhancement

KW - Preclinical evaluation

UR - http://www.scopus.com/inward/record.url?scp=84897019095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897019095&partnerID=8YFLogxK

M3 - Article

VL - 76

SP - 32

EP - 38

JO - Eksperimental'naya i Klinicheskaya Farmakologiya

JF - Eksperimental'naya i Klinicheskaya Farmakologiya

SN - 0869-2092

IS - 10

ER -